Skip to main content

etakafusp alfa

Generic: Etakafusp Alfa

etakafusp alfa: 2 clinical trials tracked.

etakafusp alfa evidence translation

What we can confirm

2 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about etakafusp alfa, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 2 study sponsors
Clinical Trials (2)

Phase 1 Clinical Trial of a Personalized Cancer Immunotherapeutic (PCI) Strategy +/- AB248 (CD8-selective IL-2 Mutein Fusion Protein) in Patients With a New Diagnosis of Triple Negative Breast Cancer Undergoing Neoadjuvant Chemoimmunotherapy

NCT07300475·Phase 1·FLNA
Not yet recruiting

Primary endpoint: Treatment-emergent adverse events (TEAEs)

InterventionalRandomizedopen30 targetStarted 2026-03Completion 2034-121 site · United StatesWashington University School of Medicine

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

NCT07037758·Phase 1·AMGN
Recruiting

Primary endpoint: Number of Participants with Treatment-emergent Adverse Events (TEAEs)

Interventionalopen380 targetStarted 2025-09Completion 2031-0119 sites · South Korea, Turkey (Türkiye), United StatesAmgen